Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trained immunity reprogramming study in thyroid cancer, colon cancer, and melanoma
NL-OMON53801Terminated
- Sponsor
- Interne Geneeskunde
- Start
- Sep 2022
- Modality
- Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label trial of HDL-MDP nanoparticles in thyroid cancer, colon cancer and melanoma (3 cohorts), sponsored by Interne Geneeskunde. Started Sep 2022; status: terminated.
02
Drugs
HDL-MDP nanoparticles
03
Conditions
thyroid cancercolon cancermelanoma
Beyond the preview
Go deeper on NL-OMON53801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53801.